In a recent global study of 75 patients with relapsed or refractory B-ALL treated with tisagenlecleucel (CD19-targeted CAR T cells), the overall complete remission rate within 3 months was 81%, and the 12-month event-free and overall survival rates were 50% and 76%, respectively [65]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.